作为抑郁症的目标的HPA轴
1Department of Psychosomatic Medicine and Psychotherapy, Medical Park Chiemseeblick, Rasthausstr, 25, 83233 Bernau am Chiemsee, Germany.
Current neuropharmacology
|August 15, 2023
概括
大型抑郁症 (MDD) 涉及到下丘脑-垂体-上腺 (HPA) 轴. 针对HPA轴组件的目标显示出有希望,诊断测试可以实现个性化MDD治疗.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 内分泌学 在内分泌学.
背景情况:
- 重度抑郁症 (MDD) 是一种普遍存在的,与压力相关的心理健康状况,影响全球20%的人口.
- 脑下垂体-垂体-上腺 (HPA) 轴的异常与MDD的发展密切相关.
- 现有研究强调了HPA轴在MDD病理生理学中的中心作用.
研究的目的:
- 审查针对MDD治疗的HPA轴的当前治疗策略.
- 在HPA轴中探索新药标的潜力.
- 强调MDD中精准医学诊断工具的重要性.
主要方法:
- 对MDD的HPA轴调节器进行的临床前和临床研究的审查.
- 研究候选药物,包括CRH1受体抗剂,血管压素V1B受体抗剂,葡萄糖皮质体受体抗剂和FKBP5抗剂.
- 分析诊断测试,如德克萨米他-皮质红蛋白释放激素 (dex-CRH) 测试和分子德克萨米他抑制 (mDST) 测试.
主要成果:
- 瓦索普林V1B受体对抗剂和葡萄糖皮质体受体对抗剂已经显示了迄今为止最有前途的临床结果.
- FKBP5对抗剂显示出临床前的支持,并可能调解胺的作用.
- HPA轴失调仅存在于MDD患者的一个子集中.
结论:
- 针对特定的HPA轴组件为MDD治疗提供了潜力,特别是在患有HPA轴变化的患者子组中.
- 诊断测试对于识别将从HPA轴向治疗中受益的患者至关重要.
- 实施伴随诊断将促进准确医学方法,以量身定制MDD治疗.
相关概念视频
Hypothalamic-Pituitary Axis
60.5K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
60.5K
Depression: Overview
277
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
277
Depressive Disorders: Etiology
139
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
139
Depressive Disorders: MDD and Dysthymia
175
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
175
Antidepressant Drugs: MAOIs and Other Agents
274
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
274
Psychosis: Goals of Pharmacotherapy
166
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
166


